Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial. - Fang, Yu; Su, Ning; Zou, Qihua; Cao, Yi; Xia, Yi; Tang, Linquan; Tian, Xiaopeng; Liu, Panpan; Cai, Qingqing (BMC Medicine, 2023)